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Ethnopharmacological relevance: Gentiopicroside (GPS), one of iridoid glucoside representatives, is the
most potential active component in Gentiana rigescens Franch. ex Hemsl and Gentiana macrophylla Pall.
These two herbs have been used to treat jaundice and other hepatic and billiary diseases in traditional
Chinese medicine for thousands of years.
Aim of the study: This study aimed to investigate the protective effects and mechanisms of GPS on α-
naphthylisothiocyanate (ANIT) induced cholestatic liver injury in mice.
Materials and methods: Mice were treated with GPS (130 mg/kg, ig) for 5 consecutive days. On the third
day, mice were given a single dose of Alpha-naphthylisothiocyanate (75 mg/kg, ig). Serum biochemical
markers and individual bile acids in serum, liver, urine and feces were measured at different time points
after ANIT administration. The expression of hepatic bile acid synthesis, uptake and transporter genes as
well as ileum bile acid transporter genes were assayed.
Results: In this study, ANIT exposure resulted in serious cholestasis with liver injury, which was de-
monstrated by dramatically increased serum levels of ALT, ALP, TBA and TBIL along with TCA CA, MCAs
and TMCAs accumulation in both liver and serum. Furthermore, ANIT signiﬁcantly decreased bile acid
synthesis related gene expressions, and increased expression of bile acid transporters in liver. Continuous
treatment with GPS attenuated ANIT-induced acute cholestasis as well as liver injury and correct the
dyshomeostasis of bile acids induced by ANIT. Our data showed that GPS signiﬁcantly upregulated the
hepatic mRNA levels of synthesis enzymes (Cyp8b1 and Cyp27a1) and transporters (Mrp4 Mdr1 and Ost-
β) as well as ileal bile acid circulation mediators (Asbt and Fgf15), accompanied by serum and hepatic bile
acid levels decrease and further urinary and fecal bile acid levels increase.
Conclusion: GPS can change bile acids metabolism which highlights its importance in mitigating cho-
lestasis, resulting in the marked decrease of intracellular bile acid pool back toward basal levels. And the
protective mechanism was associated with regulation of bile acids-related transporters, but the potential
mechanism warrants further investigation.
& 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Ireland Ltd. This is an open acces
D ID 88708.
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. Han),1. Introduction
Bile acids (BAs), which originate from cholesterol, are amphi-
pathic molecules that not only facilitate the uptake of lipids but
also interact with the aqueous environment (Tang et al., 2014). The
enterohepatic circulation of BAs play important role in stimulating
lipid solubilization, regulating cholesterol homeostasis and med-
iating metabolic signaling. While the homeostasis of BAs that
depends on intact enterohepatic circulation may be disturbed by
genetic defects, drug toxicities, hepatobiliary malignancies ands article under the CC BY-NC-ND license
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(Zhang et al., 2012). Cholestasis is characterized by progressive
distribution or impairment in bile ﬂow, leading to liver diseases. It
includes intrahepatic and extrahepatic cholestasis (Popper, 1968).
Intrahepatic cholestasis is usually induced by drugs (Plaa and
Priestly, 1976), chemicals (Plaa and Priestly, 1976), pregnancy (de
Pagter et al., 1976; Lucena et al., 2003), primary biliary cirrhosis
(PBC) (Jansen, 2000; Fiorucci and Baldelli, 2009), and hepatitis
(Trinchet et al., 1994). Extrahepatic cholestasis is associated with
gallstones, primary sclerosing cholangitis (PSC) (Hofmann, 2002),
or pancreatic tumor. Interruption of bile ﬂow leads to accumula-
tion of bilirubin, cholesterol and toxic BAs in liver and cause fur-
ther hepatotoxicity.
So far, ursodeoxycholic acid (UDCA) is the only approved drug
by Food and Drug administration (FDA) for cholestasis, therefore,
development of new therapeutic approaches is required due to the
limited efﬁcacy of UDCA (Hirschﬁeld et al., 2010). Gentiana ri-
gescens Franch. ex Hemsl has been used to treat jaundice (China
Pharmacopoeia Committee, 2010) and other hepatic and billiary
diseases in traditional Chinese medicine. Gentiopicroside (GPS),
the representative iridoid glucoside, is the most potential active
component in this herb (Kondo et al., 1994). Based on current
reports and experiments, GPS exerts certain protective effect on
hepatobiliary system (Lian et al., 2010; Wang et al., 2010; Kondo
et al., 1994). Our preliminary data also showed that GPS facilitated
bile ﬂow in rabbit and rat (Data not shown) and improved
symptoms of cholestasis induced by ANIT in mice.
In present study, Alpha-naphthylisothiocyanate (ANIT) is a
successful chemical to stimulate cholestasis in mice, which was
conﬁrmed by our previous work and publication ﬁndings. Our
previous study showed that the concentration of conjugated BAs
positively correlated with the degree of cholestasis induced by
ANIT, and the change of BAs in serum could be used as indicators
to predict liver injury (Yang et al., 2012). Therefore, in this study,
we target on BAs proﬁles to discover mechanism of ANIT toxicity
and protective effect of traditional Chinese medicine(TCM).
Here, we investigated the inﬂuence of GPS on bile acid bio-
synthesis, metabolism and transport as well as the correlation
between GPS-effect on improving cholestasis caused by ANIT and
the change of bile acid proﬁle.2. Materials and method
2.1. Materials and instruments
ANIT was purchased from Sigma-Aldrich (St. Louis, Missouri,
USA). Cholic acid (CA), α-mouse cholic acid (α-MCA), β-mouse
cholic acid (β-MCA), ω-mouse cholic acid (ω-MCA), deoxycholic
acid (DCA), chenocholic acid (CDCA), lithocholic acid (LCA), urso-
deoxycholic acid (UDCA), hyodesoxycholic acid (HDCA), gly-
cocholicacid (GCA), taurocholic acid (TCA), tauro-α-mouse cholic
acid (T-αMCA), tauro-β-mouse cholic acid (T-βMCA), tauro-ω-
mouse cholic acid (T-ωMCA), glycodeoxycholic (GDCA), taur-
odeoxycholic acid (TDCA), glycochenodeoxycholic acid (GCDCA),
taurochenodeoxycholic acid (TCDCA), glycoursodeoxycholic acid
(GUDCA), tauroursodeoxycholic acid (TUDCA), taurohyodesoxy-
cholic acid (THDCA), glycolithocholic acid (GLCA), taurolithocholic
acid (TLCA), Alpha- naphthylisothiocyanate (ANIT) and olive oil
were purchased from Sigma-Aldrich. Ammonium Acetate, formic
acid, methanol (HPLC-grade) and acetonitrile (HPLC-grade) were
purchased from Fisher Scientiﬁc (Nepean, Ontario, Canada). The
standard compounds of gentiopicroside was purchased from
Shanghai R&D Center for Standardization of Chinese Medicines
and characterized by NMR and mass spectral data and comparison
with literature values. The purities of these compounds weredetermined to be more than 98% by HPLC analysis. Ultrapure
water was puriﬁed with a Milli-Q system (Millipore, Bedfordshire,
UK). The other solvents of analytical grade were purchased from
Shanghai Chemical Factory (Shanghai, China).
2.2. Animals
C57BL/6J (clean grade, 25 g, 8–10week age) were obtained from
the Laboratory Animal Center of Shanghai University of Traditional
Chinese Medicine (SHUTCM, Shanghai). The animals were housed
at 20 (72) °C with relative humidity at 60–70%. The animal wel-
fare were strictly complied with the Guide for the Care and Use of
Laboratory Animals, and the protocols for the animals experiment
was approved by the Institutional Animal Committee of Shanghai
University of Traditional Chinese Medicine (Permit number: SCXK
(Hu) 2012-0002) The mice were randomly assigned into ten
groups, Vehicle group (n¼8), ANIT-6 h group (n¼8) ANIT-24 h
group (n¼8), ANIT-48 h group (n¼8), ANIT-96 h group (n¼8),
ANIT-144 h group (n¼8), GPSþANIT-48H group (n¼8), GPS group
(n¼8). GPSþANIT-48H and GPS group were pretreated with GPS
(130 mg/kg dissolved in normal saline) 5 consecutive days. On the
third day of GPS treatment, mice except vehicle group and GPS
group were given a single dose of ANIT (75 mg/kg dissolved in
olive oil) and meantime vehicle group was administered in-
tragastrically with olive oil. After different time points of ANIT
administration, the mice were sacriﬁced to obtain their blood, li-
vers and ileums. The blood samples were coagulated in 1.5 h and
were centrifuged to obtain serum at 4 °C (3000 g). Each mouse
liver was isolated and partially ﬁxed in 10% buffered formaldehyde
for further histological analysis. The left livers were immediately
transferred to the liquid nitrogen, and then were stored at 80 °C
for real-time PCR and BA proﬁle analysis.
2.3. Biochemical assay and histological study
The acquired serum was to test activity of serum alkaline
phosphatase (ALP), total bilirubin (TBIL), aspartate amino-
transferase (ALT) and concentration of total bile acid (TBA). The
liver stained with a standard hematoxylin and eosin (H&E) pro-
cedure revealed patterns of cellular labeling under the light-mi-
croscope for necrosis and other structural changes.
2.4. Quantitation of BAs
The quantiﬁcation method was improved as shown below ac-
cording to Yang et al. (2008).
2.5. Sample preparation
The previously developed UPLC-MS method was applied to
quantify BA concentrations (Yang et al., 2008). Serum were ob-
tained with 100 μl, add methanol 300 μl, the mixture was agitated
for 1 min using a vortex agitator followed by centrifugation at
20,000 g for 10 min at 4 °C. The supernatant was dried with
nitrogen. Last, the residue was dissolved in 80 μl mixture of 0.01%
acetic acid containing 5 mM ammonium acetate/methanol (45:55,
v/v) and centrifuged at 20,000 g for 10 min at 4 °C.
2.6. Chromatographic conditions
The BAs were determined by the Waters Acquity UPLC System
coupled with quadruple spectrometry (ZQ2000, waters). An AC-
QUITY UPLC BEH column (1.7 mm, 2.1 mm100 mm) heated to
45 °C was used for chromatographic separation. A gradient system
was consisted of solvent A (methanol) and solvent B (0.01% acetic
acid containing 5 mM ammonium acetate) at a ﬂow rate 0.3 mL/
Table 1
Primer sequences used for quantitative real-time PCR in this study.
Name Forward primer (5′-3′) Reverse primer (5′-3′)
β-actin GGCTGTATTCCCCTCCATCG CCAGTTGGTAACAATGCCATGT
Cpy8b1 CCTCTGGACAAGGGTTTTGTG GCACCGTGAAGACATCCCC
Cyp27a1 CCAGGCACAGGAGAGTACG GGGCAAGTGCAGCACATAG
Oatp1b2 GGGAACATGCTTCGTGGGATA GGAGTTATGCGGACACTTCTC
Ntcp, CAAACCTCAGAAGGACCAAACA GTAGGAGGATTATTCCCGTTGTG
Ost-β AGATGCGGCTCCTTGGAATTA TGGCTGCTTCTTTCGATTTCTG
Mdr1 CTGTTGGCGTATTTGGGATGT CAGCATCAAGAGGGGAAGTAATG
Mrp2 GTGTGGATTCCCTTGGGCTTT CACAACGAACACCTGCTTGG
Mrp3 CTGGGTCCCCTGCATCTAC GCCGTCTTGAGCCTGGATAAC
Mrp4 AGGAGCTTCAACGGTACTGG GCCTTTGTTAAGGAGGGCTTC
Fgf15 ATGGCGAGAAAGTGGAACGG CTGACACAGACTGGGATTGCT
Asbt GTCTGTCCCCCAAATGCAACT CACCCCATAGAAAACATCACCA
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55–62%A (1.0–2.6 min), and 62–80%A (2.6–11.4 min). The injection
volume was 5 μl. The mass spectrometer was used in selective ion
monitoring (SIM) function in the ESI-negative mode. The capillary
voltage was set at 3.0 kV, and cone voltage was 55 V. The source
temperature was 120 °C, and the desolvation temperature was
300 °C, while the desolvation gas ﬂow was set to 700 L/h, and the
cone gas ﬂow was 50 L/h.
2.7. Quantiﬁcation of mRNA
Total RNA was extracted by using Trizol (TAKARA, Dalian, Chi-
na) followed by reverse-transcription to cDNA (1 μg/μl) with re-
verse transcriptase (TAKARA, Dalian, China). Gene-speciﬁc primers
were designed using Primers 3 online (Primer sequences are
shown in Table 1). The mRNA levels were quantiﬁcation by Re-
altime-PCR (ABI step one plus, Applied Biosystems) using SYBR
Green Master Mix (TAKARA, Dalian, China). All reactions were
performed in triplicates, and thermal cycling conditions were as
follows: 2 min at 95 °C, followed by 40 cycles of 95 °C 10 s and
60 °C 30 s β-Actin was used to normalize to target mRNA levels.
2.8. Statistical analysis
All data were processed by using Excel and expressed as
Mean7SD, Pr0.05 was considered statistically signiﬁcant. PCA
analysis was applied by Simca-P software 13.0 (Umetrics, Umea,
Sweden). All graphs were generated with Graphpad Prim 6
(GraphPad Software, California, USA).3. Results
3.1. ANIT can induce hepatotoxicity and cholestasis in a time-de-
pendent manner
Biochemical analysis at different time points after ANIT ad-
ministration were conducted in our study (Fig. 1A). From the re-
sults, ANIT treatment dramatically increases serum ALT, ALP, TBA
and TBIL levels at 48 h after ANIT administration, suggesting a
severe liver injury with cholestasis. At 96 h and 144 h time point
after administration of ANIT, above parameters show a gradually
recovery trend towards to physical condition while ALT and TBA
are still different from the vehicle group at 96 h and 144 h.
3.2. Bile acid homeostasis was disturbed by ANIT exposure
Individual bile acid levels were measured by UPLC-MS and
followed by PCA analysis. From PCA score plot (Fig. 1B), vehicle,
ANIT-48 h ANIT-96 h and ANIT-144 h group separate clearly fromeach other, while ANIT-6 h and ANIT-24 h groups distribute to-
gether with vehicle group. Moreover, there is a trend of sponta-
neous recovery to physical condition after 96 h ANIT
administration.
3.3. GPS attenuates ANIT-induced hepatotoxicity and cholestasis
Time point of 48 h after ANIT administration was used to study
the protective effect of GPS. ANIT administration increases serum
ALT, ALP, TBA and TBIL levels signiﬁcantly (Fig. 2A), suggesting
ANIT successfully and maximumly induced hepatotoxicity. These
abnormally elevation induced by ANIT are attenuated by GPS
(Fig. 2A). Thus, GPS potentially protects against ANIT-induced he-
patotoxicity. Furthermore, mouse liver sections were processed
and stained by H&E for histological analysis. From Fig. 2B, ANIT
treatment induces large periportal hemorrhage, diffuse vacuoli-
zation, inﬂammatory inﬁltration and parenchymal necrosis in
comparison to vehicle liver sections. Nevertheless, these injuries
have been improved by GPS treatment. In addition, no side effect
has been observed on these serological and histological markers in
GPS alone treatment groups. Hence, GPS can signiﬁcantly attenu-
ate ANIT-induced liver injury with cholestasis.
3.4. GPS targets bile acid proﬁles against ANIT-induced hepatotoxi-
city and cholestasis
In order to evaluate the protective effect of GPS, hepatic and
serum individual bile acid levels were measured by UPLC-MS and
followed by PCA analysis (Fig. 3A and B). There are four groups
shown in the PCA score plot including vehicle, ANIT, GPS and
GPSþANIT-48 h groups. Vehicle, ANIT and GPSþANIT-48 h groups
separate signiﬁcantly, while GPS alone treatment and vehicle
grouped together. ANIT-treated group scatters far from vehicle
group, indicating a severely disrupted bile acid homeostasis after
ANIT exposure. The treatment of GPSþANIT-48 h group distributes
closer to vehicle group than ANIT group, indicating that GPS nor-
malized the ANIT-induced abnormality on bile acid levels in both
liver and serum.
As shown in Fig. 4A and B, BAs elevate remarkably in both
serum and liver after ANIT treatment. The levels of CA, β-MCA, ω-
MCA, TCA, T-ωMCA, and T-αMCA increase by 10-fold, 1.5-fold,
2-fold, 15-fold, 42-fold 4-fold and 25-fold in liver, respectively. The
levels of CA, β-MCA, ω-MCA, TCA, T-ωMCA, TDCA and T-αMCA
increase dramatically 2-fold, 100-fold, 200-fold 1000-fold, 1500-
fold, 190-fold and 200-fold in the serum, respectively. With GPS
treatment, the levels of TUDCA, TCA, T-αMCA, T-ωMCA, β-MCA, ω-
MCA and TDCA decrease in serum compared with ANIT group.
Besides, the levels of CA and TCA decrease in liver compared to
ANIT group (Fig. 4B). While CA and TCA increase in urine and feces
after GPS treatment compared with ANIT group (Fig. 5A and B),
which may indicate that the acceleration of BA excretion by GPS
treatment contributes to protective mechanism. Consequently,
GPS can attenuate ANIT-induced hepatotoxicity and cholestasis
through inﬂuence of bile acid proﬁles.
3.5. GPS change the expression of gene proﬁles involved in bile acid
synthesis, transportation and reabsorption
Our data indicate that bile acid homeostasis regulation con-
tributes to the potential mechanism of GPS protection. Therefore,
the expression levels of genes involved in bile acid biosynthesis,
metabolism and transportation were further analyzed in mice li-
vers and ileums by Real-time PCR. A cluster analysis was used to
show the global expression levels of BA related genes in all groups
in a visualized heatmap. As shown in Fig. 6A, ANIT group is far
away from vehicle group, indicating ANIT-induced abnormality at
Fig. 1. ANIT administration induces most severe hepatotoxicity and cholestasis at 48 h. (A) Serum ALT, ALP activity as well as serum total bilirubin and total bile acids were
determined at time points of 6 h 24 h 48 h 96 h 144 h after ANIT administration. Data are shown as mean7S.D. (n¼8). (B) PCA score plot derives from vehicle and different
time points (6 h, 24 h, 48 h, 96 h and 144 h) group after ANIT administration using serum bile acids.
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vehicle group, suggesting its hepatoprotective effect.
As shown in Fig. 6A and B, three of the most important bile acid
biosynthesis genes (Cyp7a1, Cyp27a1 and Cyp8b1) are signiﬁcantly
down-regulated after ANIT treatment while up regulated by GPS
treatment. The mRNA levels of uptake transporters (Oatp1b2 and
Ntcp) decrease approximately 84% and 86% in the ANIT group,
respectively, while in the GPSþANIT-48 h group, these two genes
are up-regulated. The efﬂux transporters, including Mrp2, Mrp3,
Mrp4, Mdr1, Mdr3 and Ost-β are also analyzed between the dif-
ferent groups. The multidrug resistance P-glycoproteinsMdr3 gene
expression reduces after ANIT treatment but increase in
GPSþANIT-48 h group. GPS treatment can up regulate Mrp3 gene
expression which is inhibited by ANIT. Ost-β, which acts to secrete
BAs and xenobiotics from hepatocytes into blood, shows the most
signiﬁcant change after ANIT treatment. The mRNA level of Ost-β
increases 35-fold, and in GPSþANIT-48 h group, the expression
level shows even higher compared to ANIT group. The other im-
portant excretion transporter, Mdr1 gene expression increase
5-fold after ANIT treatment, and is further enhanced signiﬁcantly
by GPS treatment. Moreover, GPS treatment alone, an increase of
Mrp4, Mdr1 and Ost-β can be observed.
Additionally, enterohepatic circulation contributes primarily to
the reabsorption of BAs. Bile is the driving force to transport BAs
from hepatocyte through the bile duct to reach the small intestine
where most (495%) of the BAs are reabsorbed and returned to theliver via portal blood. The mRNA levels of Fgf15 and Asbt in ileum
were also studied. GPS can increase the relative expression of
these two genes against the down-regulation caused by ANIT ad-
ministration (Fig. 6C).4. Discussion
One important characteristic of cholestasis is interruption of
bile ﬂow, which leads to disorder of BAs metabolism. In the
meantime, proper regulation of BAs is typically important for liver
injury and cholestasis protection (Hirschﬁeld et al., 2010; Meng
et al., 2015). The elevation of BAs coinciding with cholestasis could
damage the hepatocytes and result in necrosis or apoptosis de-
pending on its structure and concentration (Hofmann, 1999).
ANIT-treated mice were established as a successful cholestasis
model in a dose- and time-dependent manner. Based on up-date
literatures, elevation of ALP, ALT, high degree of inﬂammation,
epithelial necrosis and obstruction could be observed at 75 mg/kg
of ANIT orally administration from 24 h to 144 h (Kossor et al.,
1995; Liu et al., 2003; Cui et al., 2009). Moreover, ultrastructural
level some alterations in the tight junctions between hepatocytes
were seen 6 h after ANIT administration, focal necrosis in liver
started at 24 h and reached most severe at 48 h. Although ap-
proximately 80% of ANIT were excreted to the urine, expired gases,
and feces at 72 h, the toxicity of ANIT takes more time to dispel
Fig. 2. GPS alleviates ANIT-induced hepatotoxicity and cholestasis at 48 h after ANIT administration. (A) Increased serum ALT and ALP activity, as well as serum total bilirubin
and total bile acid levels elevated by ANIT administration at 48 h were signiﬁcantly reduced by GPS treatment. Data are shown as mean7S.D (n¼8). *po0.05 versus ANIT;
#po0.05 verus vehicle. (B) H&E stained liver sections (100 magniﬁcation) at 48 h are demonstrated after ANIT administration. Areas of severe liver necrosis and hy-
perplastic bile duct cytoderm were marked by arrows.
Fig. 3. : GPS changes bile acid proﬁles and protects against liver injury and cholestasis. PCA score plot derives from four representative Vehicle, ANIT, GPS and GPSþANIT-
48 h groups using serum bile acids (A) and hepatic bile acids (B).
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Fig. 4. GPS can decrease elevated BAs caused by ANIT administration in liver and serum. Individual bile acids were detected in the serum (A) and liver (B) of different groups
at 48 h after ANIT administration. All data are expressed as mean7S.D. (n¼6). *po0.05 versus ANIT; #po0.05 verus vehicle.
Fig. 5. : GPS can increase BA levels in urine and feces. Individual bile acids were detected in urine (C) and feces (D) of different groups at 24 h and 48 h after ANIT
administration. All data are expressed as mean7S.D. (n¼6). *Po0.05 versus ANIT; #po0.05 verus vehicle.
X. Tang et al. / Journal of Ethnopharmacology 194 (2016) 63–7168
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with previous evidence, our data showed that ALT and TBA were
still different from the vehicle group at 144 h, which indicates liver
dysfunction at some extent (Becker and Plaa, 1965; Yang et al.,
1998). Hence, in our study, the dose at 75 mg/kg was selected to
cause a modest cholestasis animal model. In addition, time point
of 48 h after ANIT administration was chosen according to the
literature and our previous data. From the results, serum ALT, ALP,
TBIL activity, TBA concentration, and histological analysis indicated
that liver injury with cholestasis was successfully induced by ANIT.
ANIT can increase TBA and individual BAs concentration (Cui et al.,
2009). The most signiﬁcant elevation can be observed in taurine-
conjugated BAs rather than glycine-conjugated ones in mice as
presented in this study. ANIT treatment inhibits bile acid synthesis
and enhances BAs efﬂux from the liver.
As reported, TCMs has been widely used to protect against liver
injury and cholestasis. Among the TCMs, numerous herbs which
contain iridoids unfold strong hepatoprotective effects. A TCM
formula ‘Yin Chen Hao decoction’, which consists of several ir-
idoids attenuates cholestasis, prevents ﬁbrosis and alleviates al-
coholic fatty liver in rats and the therapeutic effect of it could be
attributed to the regulation of Oatp2, Ntcp, Mrp2, and Bsep (Lee
et al., 2007; Gao and Zhou, 2005). Geniposide and Swertiamarin
are the major effective iridoid of Gardenia jasminoides Ellis and
Swertia mussotii Franch respectively. Studies show that they can
evidently relieve hepatocyte injuries and help to maintain the
homeostasis of BA metabolism though the regulation of BA related
genes, thereby modulating the balance of liver steroid metabolism,
which might be part of the mechanisms of hepatoprotective ef-
fects of iridoids. (Wang et al., 2013;Tian et al., 2014). GPS is an
iridoid glucoside, which also exerts hepatoprotective effect against
acetaminophen and Galactosamine/Lipopolysaccharide (Wang
et al., 2010; Lian et al., 2010). However, the choleretic effect of GPS
has not been well studied. In our data, with GPS treatment, a
signiﬁcant reduction of BAs concentration could be observed, in-
dicating GPS was partly beneﬁcial to the excretion of BAs and
maintenance of BAs homeostasis. The decrease of BAs concentra-
tion caused by other chemical agents, such as GW4064 (Liu et al.,
2003), contributed to the attenuation of cholestasis. The relation-
ships between the hepatobiliary-protective effect of GPS and BAs
regulation was described for the ﬁrst time.
When biliary obstruction occurs, BAs alteration may exhibit
compensatory effect to reduce overload hepatic BAs and simulta-
neously transform via hydroxylation and conjugation to counteract
toxicity (Zollner et al., 2006). There was an underlying mechanism
to drive the excretion of BAs. Mdr P-glycoproteins (MDR1 and
MDR3), transport phospholipids, BAs and cholesterol from liver to
bile (van Helvoort et al., 1996), and improve the solubility of BAs to
alleviate potential toxicity. In addition, MDR1 deﬁciency in human
leads to progressive familial intrahepatic cholestasis type3 (PFIC3)
(Strautnieks et al., 1998). This malfunction can also be observed in
primary biliary cirrhosis (PBC) patients (Zollner et al., 2003). In our
research, GPS up-regulated the lower Mdr1 expression levelFig. 6. GPS changes the expression of gene proﬁles involved in bile acid synthesis,
transportation and reabsorption. (A) The colors on the heatmap correspond to the
average gene expression. Red represents up-regulation, while green represents
down-regulation. Hierarchical clustering separates X axis of heat map represents
the average gene expression level of 5 samples, while Y axis stands for different
groups. Red color means the high value of gene expression, and green one re-
presents the opposite. (B) Quantitative real-time PCR analysis was performed to
measure the gene expression of Cpy8b1, Cyp27a1, Oatp1b2, Ntcp, Mdr1, Ost-β, Mrp2,
Mrp3 and Mrp4 in liver. *po0.05 versus ANIT; #po0.05 verus Vehicle.
(C) Quantitative real-time PCR analysis was performed to measure the gene ex-
pression of Asbt and Fgf15 in ileum. *po0.05 versus ANIT; #po0.05 verus vehicle.
(For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article)
X. Tang et al. / Journal of Ethnopharmacology 194 (2016) 63–7170caused by ANIT. Moreover, GPS can induce Mdr1 expression level,
which indicated GPS could take part in accelerating phospholipids
and BAs circulation to attenuate cholestasis in liver. OST-β ex-
presses at the basolateral membranes mediates the BAs export.
The expression of OST-β is highly dysregulated in PBC patients and
cholestasis animal models (Boyer et al., 2006). The signiﬁcance of
OST-β induction raised the possibility of enhanced BA excretion.
GPS treatment can further enhanced the Ost-β induction to speed
up BAs efﬂux. Furthermore, GPS alone treatment signiﬁcantly in-
duce Ost-β expression level. Therefore, GPS could participate in the
physiological regulation of BA excretion during hepatic toxic BAs
accumulation. Mrp2 expression was also induced by GPS treat-
ment, which correlated with the bile ﬂow increase observed in our
previous study. However, in the ANIT administration group, Mrp2
mRNA level did not show signiﬁcant change. Our ﬁndings on GPS
were parallel with the conclusion from Miura's study that genipin,
another metabolites of iridoid glucoside, prevented liver injury at
the MRP2 protein level rather than the mRNA level (Shoda et al.,
2004). We assumed that GPS could play against the higher con-
sumption of GSH by ANIT exposure, which further decrease the
transportation of conjugated ANIT-GPS through Mrp2 into bile
with GPS also accelerating bile ﬂow. Therefore, the GPS treatment
lowered toxicity in the bile duct and protected against liver injury.
Nevertheless, further studies are necessary to fully explain this
hypothesis.
GPS and its metabolites showed certain bioavailable and he-
patoprotective activities (Zeng et al., 2013; Wang et al., 2004). GPS
alone treatment has non-effect on liver damage or amino-
transferase changes, making GPS a potential drug candidate to
treat hepatobiliary diseases in future study.
In conclusion, we highlight the protective effect of GPS on BAs
proﬁles in mitigating cholestasis induced by ANIT, Target proﬁling
analyses of BAs contribute most in the evaluation of herb protec-
tion against liver injury. However, we are unable to conclude
whether the toxicity caused by ANIT was antagonized by GPS
treatment causing BAs homeostasis to normalize or GPS can re-
duce the accumulation of BAs in the liver alleviating the liver in-
jury induced by ANIT. The potential mechanisms require further
study to identify.Acknowledgment
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